Clinical Scorecard: Frequency of CSF HIV Viral Escape and Its Relationship with Neurocognitive Outcomes in Survivors of HIV-Related Meningitis: A Cohort Analysis

At a Glance

Key Highlights

• Secondary CSF HIV viral escape was highly prevalent (43%) among survivors of HIV-associated meningitis.
• CSF HIV viral escape was associated with better neurocognitive outcomes at 3 months post-meningitis.
• Individuals with secondary CSF HIV viral escape were more likely to be antiretroviral therapy (ART)-naïve and exhibit CSF pleocytosis.

Guideline-Based Recommendations

Diagnosis

• Confirm cryptococcal meningitis by CSF cryptococcal antigen testing.
• Diagnose tuberculous meningitis by microbiological confirmation or uniform research case definitions.
• Perform paired plasma and CSF HIV-1 viral load testing to identify CSF HIV viral escape.

Management

• Consider ART status when evaluating CSF HIV viral escape; note higher prevalence in ART-naïve individuals.
• Monitor and manage neurocognitive impairment in survivors of HIV-associated meningitis.

Monitoring & Follow-up

• Conduct neurocognitive testing at 3 months post-meningitis using standardized neuropsychological batteries.
• Use composite quantitative neurocognitive performance scores (QNPZ-8) to assess cognitive outcomes.

Risks

• Recognize that HIV-associated cryptococcal and tuberculous meningitis have approximately 25% acute mortality.
• Be aware that about half of survivors experience neurocognitive impairment.

Patient & Prescribing Data

Adults with HIV-associated cryptococcal or tuberculous meningitis, including ART-naïve and ART-experienced individuals

Among participants on ART, 28% had secondary CSF viral escape; among ART-naïve, 49% had viral escape, with 88% of ART regimens being dolutegravir-based.

Clinical Best Practices

• Perform paired plasma and CSF HIV viral load testing at baseline in meningitis survivors to detect CSF viral escape.
• Use validated neurocognitive testing in the patient’s preferred language to assess cognitive function post-meningitis.
• Interpret neurocognitive scores relative to an HIV-negative reference cohort to identify impairment severity.
• Consider ART status and CSF pleocytosis as factors associated with CSF HIV viral escape.
• Apply multiple linear regression models to adjust for confounders when assessing associations between viral escape and neurocognitive outcomes.

References

• Winston A et al. Consensus case definition for CSF HIV viral escape
• Uniform tuberculous meningitis research case definition
• Neurocognitive testing standardization in Ugandan cohorts